Filing Details
- Accession Number:
- 0001140361-12-023821
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-05-09 13:15:44
- Reporting Period:
- 2012-05-07
- Filing Date:
- 2012-05-09
- Accepted Time:
- 2012-05-09 12:15:44
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
874716 | Idexx Laboratories Inc | IDXX | In Vitro & In Vivo Diagnostic Substances (2835) | 010393723 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1377232 | Phd J Michael Williams | One Idexx Drive Westbrook ME 04092 | Corporate Vice President | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2012-05-07 | 20,440 | $41.94 | 31,124 | No | 4 | M | Direct | |
Common Stock | Disposition | 2012-05-07 | 24,352 | $88.19 | 6,772 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Incentive Stock Option (right to buy) | Disposition | 2012-05-07 | 3,758 | $0.00 | 3,758 | $41.94 |
Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2012-05-07 | 16,682 | $0.00 | 16,682 | $41.94 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2014-02-13 | No | 4 | M | Direct | |
0 | 2014-02-13 | No | 4 | M | Direct |
Footnotes
- Includes 79 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on 03/30/2012.
- The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $88.07 to $88.40, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
- Grant of options to buy shares of common stock becomes exercisable as to 1,374 shares on 02/14/2011, and the remaining 2,384 shares on 02/14/2012.
- Grant of options to buy shares of common stock becomes exercisable as to 4,088 shares on 02/14/2008, 02/14/2009 and 02/14/2010, 2,714 shares on 02/14/2011, and the remaining 1,704 shares on 02/14/2012.